Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL15822811 | 0.86 | SLC22A1 (0.71) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL10352758 | 0.85 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3414877 | 0.85 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL29213158 | 0.85 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL1204718 | 0.85 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5687676 | 0.85 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL17727894 | 0.84 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL10536044 | 0.84 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL10703403 | 0.83 | SLC22A1 (0.67) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL227484 | 0.83 | SLC22A1 (0.67) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457244-A | Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof | 瀚海新拓(杭州)生物医药有限公司 | 2021-03-09 | — | — | CN | claimed |
| US-10427982-B2 | Method of carbon coating on nanoparticle and carbon coated nanoparticle produced by the same | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2019-10-01 | — | — | US | claimed |
| US-20170081248-A1 | METHOD OF CARBON COATING ON NANOPARTICLE AND CARBON COATED NANOPARTICLE PRODUCED BY THE SAME | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2017-03-23 | — | — | US | claimed |
| EP-3144277-A1 | METHOD OF CARBON COATING ON NANOPARTICLE AND CARBON COATED NANOPARTICLE PRODUCED BY THE SAME | Korea Institute of Energy Research (KR) | 2017-03-22 | — | — | EP | claimed |
| US-9512154-B2 | 18FDG multimeric positron emission tomography imaging agents | MISRA, PREETI | 2016-12-06 | — | — | US | claimed |
| EP-2872246-A2 | FUEL CELL APPARATUS, COMPOSITION AND HYDROGEN GENERATOR | Prometheus Wireless Limited (GB) | 2015-05-20 | — | — | EP | claimed |
| US-20140024803-A1 | 18FDG MULTIMERIC POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS | MISRA, PREETI | 2014-01-23 | — | — | US | claimed |
| WO-2014013246-A2 | FUEL CELL APPARATUS, COMPOSITION AND HYDROGEN GENERATOR | PROMETHEUS WIRELESS LIMITED (GB) | 2014-01-23 | — | — | WO | claimed |
| EP-0405344-B1 | 2-AMINO-1,2,3,4,-TETRAHYDRONAPHTHALENE DERIVATIVES WITH CARDIOVASCULAR ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.p.A. (IT) | 1993-09-01 | — | — | EP | claimed |
| EP-0405344-A2 | 2-Amino-1,2,3,4,-tetrahydronaphthalene derivatives with cardiovascular activity, process for their preparation and pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.p.A. (IT) | 1991-01-02 | — | — | EP | claimed |
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | AUBURN UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| CN-117209361-B | Bisphenol F preparation method | 山东富宇石化有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117209361-A | Bisphenol F preparation method | 山东富宇石化有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-112105608-B | Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one | 因赛特公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230176003-A1 | ARSENIC DETECTOR AND METHOD OF USE | BREWER SCIENCE, INC. | 2023-06-08 | — | — | US | disclosed |
| US-4044123-A | ANTIBIOTICS | SCHERING CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
| US-4002608-A | ANTIBACTERIALS | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4002742-A | 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4000262-A | 5-EPI-AMINO AND 5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES 1-N-ALKYL-5-EPI-AMINO AND 1-N-ALKYL-5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000261-A | 5-EPI-4,6-DI-O-(AMINOGLYCOSYL)-2-DEOXYSTREPTAMINES, METHODS FOR THEIR MANUFACTURE AND INTERMEDIATES USEFUL THEREIN, METHODS FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957757-B2 | Method for preparing stabilized metal ion ligand nanocomplex and compositions thereof | NSFL1C, SOD1, CLTC | SLC22A1 1244/4885SLC22A2 1224/4885ALDH1A1 3974/4885 |
| US-20140024803-A1 | 18FDG MULTIMERIC POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS | MPI, PARP1, PAICS | SLC22A1 610/4885SLC22A2 639/4885ALDH1A1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.